hackint0sh/New-Dataset huggingface dataset:
nctId: NCT06282848 id: HongKongPU_Optometry4 briefTitle: Pharmacological and Non-pharmacological Treatment Effects on Children With Different Predicted Myopia Progression Rate overallStatus: RECRUITING date: 2024-01-01 date: 2026-12 date: 2026-12 date: 2024-02-28 date: 2024-03-07 name: The Hong Kong Polytechnic University class: OTHER name: The University of Hong Kong briefSummary: The goal of this clinical trial is to compare pharmacological and non-pharmacological treatment effects on the children with different predicted myopia progression rate measured by modified multifocal electroretinogram. The main questions it aims to answer are:
Researchers will compare the changes of refractive errors and axial length after different types of interventions and investigate the relations between the parameters of mfERG responses and the thicknesses of retinal layers and choroid. conditions: Myopia studyType: INTERVENTIONAL phases: NA allocation: RANDOMIZED interventionModel: PARALLEL interventionModelDescription: Randomized clinical trial primaryPurpose: PREVENTION masking: DOUBLE maskingDescription: Double-blinded whoMasked: PARTICIPANT whoMasked: INVESTIGATOR count: 80 type: ESTIMATED name: Atropine 0.05% name: DIMS lens measure: Subjective refraction measure: Axial length measure: mfERG responses measure: Retinal and choroidal thickness sex: ALL minimumAge: 7 Years maximumAge: 9 Years stdAges: CHILD facility: School of Optometry, Hong Kong Polytechnic University status: RECRUITING city: Hong Kong zip: 00000 country: Hong Kong name: Henry HL Chan, PhD role: CONTACT phone: 85227667937 email: henryhl.chan@polyu.edu.hk name: Kaiyip Choi, PhD role: CONTACT phone: 85234002934 email: kaiyip.choi@polyu.edu.hk lat: 22.27832 lon: 114.17469 typeAbbrev: ICF hasProtocol: False hasSap: False hasIcf: True label: Informed Consent Form date: 2023-03-02 uploadDate: 2024-02-21T22:59 filename: ICF_000.pdf size: 234773 hasResults: False
nctId: NCT06282835 id: 2023KY242 briefTitle: Eravacycline Combination Therapy for MRAB overallStatus: RECRUITING date: 2024-01-26 date: 2024-10-31 date: 2024-12-31 date: 2024-02-28 date: 2024-02-28 name: Fujian Medical University Union Hospital class: OTHER briefSummary: The goal of this observational study is to learn about the eravacycline combination therapy in multidrug-resistant acinetobacter gaumannii pneumonia. The main question is to evaluate the the effectiveness and safety.
Participants will be given Eravacycline and Polymyxin，or other antibiotcs that the Investigator considered suitable. During the clinical trial, participants will be monitored for blood drug concentrations and drug concentrations in the ELF (Epithelial Lining Fluid。Clinical efficacy rate and microbiological clearance rate will be assessed at the same time conditions: Pulmonary Infection conditions: Pneumonia, Bacterial conditions: Acinetobacter Baumannii studyType: OBSERVATIONAL observationalModel: COHORT timePerspective: PROSPECTIVE count: 20 type: ESTIMATED name: Eravacycline Injection measure: Clinical Responded Rate measure: The microbiological clearance rate measure: The all-cause mortality rate within 28 days measure: "Incidence Rate of Adverse Event sex: ALL minimumAge: 18 Years stdAges: ADULT stdAges: OLDER_ADULT facility: Fujian Medical University Union hospital status: RECRUITING city: Fuzhou state: Fujian zip: 350000 country: China name: Hui Zhang, Phd role: CONTACT phone: 13015723860 email: xhzh@fjmu.edu.cn lat: 26.06139 lon: 119.30611 hasResults: False
nctId: NCT06282822 id: HFpEF-SWE briefTitle: Shear Wave Elastography for Diagnosis of Heart Failure With Preserved Ejection Fraction overallStatus: NOT_YET_RECRUITING date: 2024-03-01 date: 2024-10-31 date: 2025-03-01 date: 2024-02-28 date: 2024-02-28 name: First Hospital of China Medical University class: OTHER briefSummary: The diagnosis of heart failure with preserved ejection fraction (HFpEF) is often complex. Echocardiography has the advantages of being a non-invasive, simple operation, low price, and high repeatability, and is of great value in the diagnosis of HFpEF. However, the current echocardiographic assessment of left ventricular diastolic dysfunction and elevated filling pressure is based on multi-parameter indirect judgment, and new parameters are urgently needed to achieve accurate judgment of left ventricular diastolic function and an accurate diagnosis of HFpEF. Myocardial stiffness refers to the ability of the myocardium to undergo stress and strain. It is an important part of the pathophysiology of cardiac diastolic dysfunction and an important parameter for clinical evaluation of the diastolic function of HFpEF. Shear-wave elastography is a novel ultrasound-based elastography technology. Based on the shear wave generated by the remote induction of the radiation force of the focused ultrasound beam, the hardness of myocardial tissue can be measured quantitatively, locally, and noninvasively, and the change in myocardial stiffness in patients with HFpEF can be directly reflected. Currently, no relevant studies have applied shear-wave elastography to the diagnosis of HFpEF. This study aims to identify changes in myocardial stiffness measured by shear-wave elastography in patients with HFpEF based on a multicenter study and apply myocardial stiffness parameters to the diagnosis of HFpEF. conditions: Shear Wave Elastography conditions: Heart Failure With Preserved Ejection Fraction studyType: OBSERVATIONAL observationalModel: COHORT timePerspective: PROSPECTIVE count: 800 type: ESTIMATED name: Transthoracic echocardiography measure: Shear wave velocity sex: ALL minimumAge: 18 Years stdAges: ADULT stdAges: OLDER_ADULT hasResults: False
nctId: NCT06282809 id: CSP3325 briefTitle: The HistoSonics Edison™ System for Treatment of Pancreatic Adenocarcinoma Using Histotripsy acronym: GANNON overallStatus: NOT_YET_RECRUITING date: 2024-06 date: 2025-07 date: 2026-01 date: 2024-02-28 date: 2024-04-11 name: HistoSonics, Inc. class: INDUSTRY briefSummary: The purpose of this trial is to evaluate the safety of the HistoSonics Edison System for the destruction of pancreatic adenocarcinomas using histotripsy. conditions: Pancreas Cancer conditions: Adenocarcinoma of the Pancreas conditions: Pancreatic Cancer conditions: Tumor of Pancreas studyType: INTERVENTIONAL phases: NA allocation: NA interventionModel: SINGLE_GROUP interventionModelDescription: Prospective multi-center, single-arm, feasibility trial. primaryPurpose: TREATMENT masking: NONE count: 50 type: ESTIMATED name: HistoSonics Edison™ System for the treatment of pancreatic adenocarcinoma using histotripsy measure: Evaluate the safety of the HistoSonics Edison System for the destruction of pancreatic adenocarcinomas using histotripsy sex: ALL minimumAge: 18 Years stdAges: ADULT stdAges: OLDER_ADULT facility: Hospital de la Santa Creu i Sant Pau city: Barcelona country: Spain lat: 41.38879 lon: 2.15899 hasResults: False
nctId: NCT06282796 id: EPW-CABC-01 briefTitle: Early Prediction and Warning for Cardiotoxicity Due to Anthracycline-Based Breast Cancer Chemotherapy overallStatus: RECRUITING date: 2024-01-01 date: 2026-12-31 date: 2028-12-31 date: 2024-02-28 date: 2024-02-28 name: First Hospital of China Medical University class: OTHER briefSummary: This multicenter clinical study aims to build an intelligent and accurate diagnosis and dynamic prediction and early warning model of cardiotoxicity due to anthracycline-based breast cancer chemotherapy, clarify the value of the early warning model in guiding the targeted prevention of myocardial protection, providing an important theoretical basis for reducing the mortality rate of breast cancer and improving the prognosis. conditions: Breast Cancer studyType: OBSERVATIONAL observationalModel: CASE_CONTROL timePerspective: PROSPECTIVE count: 600 type: ESTIMATED name: Echocardiography measure: Left ventricular ejection fraction(unit: %) in all breast cancer patients treated with anthracycline-based chemotherapy. measure: Left ventricular global longitudinal strain (unit: %) in all breast cancer patients treated with anthracycline-based chemotherapy. sex: FEMALE minimumAge: 18 Years maximumAge: 80 Years stdAges: ADULT stdAges: OLDER_ADULT facility: Fujian Cancer Hospital status: RECRUITING city: Fuzhou state: Fujian country: China name: Weiqin Huang role: CONTACT lat: 26.06139 lon: 119.30611 facility: Dalian Friendship Hospital status: RECRUITING city: Dalian state: Liaoning country: China name: Bo Zhang role: CONTACT lat: 38.91222 lon: 121.60222 facility: Dalian Municipal Central Hospital status: RECRUITING city: Dalian state: Liaoning country: China name: Qingxiong Yue role: CONTACT lat: 38.91222 lon: 121.60222 facility: Liaoning Cancer Hospital & Institute status: RECRUITING city: Shenyang state: Liaoning country: China name: Xiaoxue Zhang role: CONTACT lat: 41.79222 lon: 123.43278 facility: The Third People's Hospital Of Chengdu status: RECRUITING city: Chengdu state: Sichuan country: China name: Min Xu role: CONTACT lat: 30.66667 lon: 104.06667 hasResults: False
nctId: NCT06282783 id: 2024-511532-27-00 briefTitle: Studying Topiramate for Re-Activating the HIV-1 Reservoir acronym: STAR overallStatus: NOT_YET_RECRUITING date: 2024-09 date: 2025-04 date: 2025-08 date: 2024-02-28 date: 2024-02-28 name: Erasmus Medical Center class: OTHER briefSummary: Even with current HIV treatments, HIV is still a lifelong disease because it hides in some long-lasting cells in the body. One of the strategies to find a cure for HIV works by finding the virus in these cells, making it visible, and then getting rid of it. This is called the 'shock and kill' approach.
Most of the people that participate in HIV cure studies are men, even though most people living with HIV around the world are women. Previous research has shown that men and women might respond differently to these treatments. So, in this study, topiramate will be investigated in both men and women. This could help us find a cure that works for everyone. conditions: HIV-1-infection conditions: Hiv conditions: HIV Infections conditions: HIV I Infection studyType: INTERVENTIONAL phases: PHASE1 phases: PHASE2 allocation: NON_RANDOMIZED interventionModel: SINGLE_GROUP primaryPurpose: TREATMENT masking: NONE count: 12 type: ESTIMATED name: Topiramate measure: Effect of topiramate as measured by cell-associated HIV RNA measure: Number of treatment-related adverse events as assessed by CTCAE v4.0 measure: Influence of sex on the primary outcome measures measure: The effect of topiramate on the size of the HIV reservoir measured by relevant assays sex: ALL minimumAge: 18 Years stdAges: ADULT stdAges: OLDER_ADULT facility: Erasmus Medical Centre city: Rotterdam country: Netherlands lat: 51.9225 lon: 4.47917 hasResults: False
nctId: NCT06282770 id: IRB#23-000444 briefTitle: Photobiomodulation for Lower Back Pain Post Spinal Fusion and Decompression Surgery overallStatus: RECRUITING date: 2023-07-01 date: 2024-07-01 date: 2025-07-01 date: 2024-02-28 date: 2024-02-28 name: University of California, Los Angeles class: OTHER briefSummary: After spinal fusion and decompression surgery there is a possible risk of developing chronic back pain. After surgery there is typically inflammation around the operation site and this inflammation can be painful and debilitating to patients.
Many possible treatment plans have been incorporated to assist the patient with recovery - notably medications, physical therapy, and braces. However, few studies have looked at laser diodes that utilize high-power laser lights that are aimed at decreasing pain and inflammation. Investigators aim to look compare patients using a back brace with laser diodes within versus those who wear a normal brace used as a placebo. Investigators will also assess the patient's surgical wound to monitor the progression of wound healing while using the brace. conditions: Spinal Fusion conditions: Chronic Lower Back Pain studyType: INTERVENTIONAL phases: NA allocation: RANDOMIZED interventionModel: CROSSOVER interventionModelDescription: Patients will come into clinic for consultation and enrollment in the study. They will have their first study visit where they will be given either and laser diode brace or a placebo brace. They will follow up with the physician after 2 weeks and then at 3, 6, 9 months and at 1 year to evaluate function and symptoms . primaryPurpose: TREATMENT masking: TRIPLE maskingDescription: Participants in this study will not be told which belt is the sham diode brace or which is the functional diode brace. The assessor of the study will also be blinded to which belt each subject has, and data will be analyzed blindly based on patient ID alone. whoMasked: PARTICIPANT whoMasked: INVESTIGATOR whoMasked: OUTCOMES_ASSESSOR count: 80 type: ESTIMATED name: Laser Diode Brace name: Sham Laser Diode Brace measure: Self-reported patient outcome questionnaires after photobiomodulation therapy - VAS measure: Self-reported patient outcome questionnaires after photobiomodulation therapy - ODI measure: Stony Brook Scar Evaluation sex: ALL minimumAge: 18 Years maximumAge: 75 Years stdAges: ADULT stdAges: OLDER_ADULT facility: Semel Institute of Neuroscience at UCLA status: RECRUITING city: Los Angeles state: California zip: 90024 country: United States name: Daniel Lu, MD, PhD role: CONTACT phone: 310-267-2975 email: DCLu@mednet.ucla.edu name: Mark Yamamoto, BS role: CONTACT phone: 424-535-9634 email: MTYamamoto@mednet.ucla.edu lat: 34.05223 lon: -118.24368 facility: UCLA Clinical and Translational Research Center status: RECRUITING city: Los Angeles state: California zip: 90095 country: United States name: Daniel Lu, MD, PhD role: CONTACT phone: 310-267-2975 email: DCLu@mednet.ucla.edu name: Adreanne Rivera, BS role: CONTACT phone: 424-946-5712 email: adreannerivera@mednet.ucla.edu lat: 34.05223 lon: -118.24368 hasResults: False
nctId: NCT06282757 id: 202302 briefTitle: Physiotherapists' Placebo or Nocebo Communication Regarding VR in CMP overallStatus: NOT_YET_RECRUITING date: 2024-04-01 date: 2024-05-01 date: 2024-05-01 date: 2024-02-28 date: 2024-03-07 name: HAN University of Applied Sciences class: OTHER briefSummary: Rationale: Chronic musculoskeletal pain (CMP) is a common and disabling condition. Physiotherapy is the most frequently administered non-pharmacological treatment option for patients with CMP and recently virtual reality (VR) was introduced in physiotherapy care as a novel treatment modality. Proper communication about physiotherapy treatment (modalities) is important to improve treatment outcomes, by applying placebo effects enhancing communication and avoiding nocebo effects enhancing communication. However, yet is still unknown to what extent this applies to communication of physiotherapists about VR in patients with CMP.
Primary study parameters: The primary study parameters are treatment credibility and treatment expectation. Treatment credibility and treatment expectations will be measured using the Dutch credibility and expectancy questionnaire (CEQ). conditions: Communication conditions: Chronic Pain studyType: INTERVENTIONAL phases: NA allocation: RANDOMIZED interventionModel: PARALLEL primaryPurpose: OTHER masking: TRIPLE whoMasked: PARTICIPANT whoMasked: INVESTIGATOR whoMasked: OUTCOMES_ASSESSOR count: 100 type: ESTIMATED name: Video placebo communication name: Video nocebo communication measure: Change in treatment expectancy measured using the Credibility and Expectancy Questionnaire (CEQ) measure: Change in treatment credibility measured using the Credibility and Expectancy Questionnaire (CEQ) measure: Change in openness to VR measured using a single question measure: Change in pain intensity measured using the Numeric Pain Rating Scale (NPRS) sex: ALL minimumAge: 18 Years stdAges: ADULT stdAges: OLDER_ADULT facility: HAN University of Applied Sciences city: Nijmegen state: Overijssel zip: 6525EN country: Netherlands name: Syl Slatman, MSc role: CONTACT phone: +31629684200 email: syl.slatman@han.nl lat: 51.8425 lon: 5.85278 hasResults: False
nctId: NCT06282744 id: OPTIMAL Arabic version briefTitle: Cross Cultural Adaptation, Validity and Reliability Test of the Arabic Version of the Outpatient Physical Therapy Improvement in Movement Assessment Log acronym: OPTIMAL overallStatus: NOT_YET_RECRUITING date: 2024-03-01 date: 2024-03 date: 2024-04 date: 2024-02-28 date: 2024-02-28 name: Cairo University class: OTHER briefSummary: Purpose of the study:
To translate, culturally adapt, and to test the validity and reliability of the Outpatient Physical Therapy Improvement in Movement Assessment Log in Arabic speaking language. conditions: Physical Performance conditions: Outpatients studyType: OBSERVATIONAL observationalModel: OTHER timePerspective: CROSS_SECTIONAL count: 880 type: ESTIMATED name: Outpatient physical therapy improvement in movement assessment log measure: validity and reliability of the Egyptian Arabic language version of Outpatient Physical Therapy Improvement Movement Assessment Log on physical therapy outpatients. sex: ALL minimumAge: 18 Years stdAges: ADULT stdAges: OLDER_ADULT hasResults: False
nctId: NCT06282731 id: ECKIRB1020407 briefTitle: The Changes of Urine Growth Factors Level overallStatus: COMPLETED date: 2013-05-31 date: 2016-09-01 date: 2017-04-27 date: 2024-02-28 date: 2024-02-28 name: En Chu Kong Hospital class: OTHER briefSummary: The Changes of Urine Growth Factors Level in Patients With Benigh Prostate Hyperplasia after medical treatment. conditions: Benign Prostatic Hyperplasia studyType: INTERVENTIONAL phases: EARLY_PHASE1 allocation: NA interventionModel: SINGLE_GROUP primaryPurpose: SCREENING masking: NONE count: 74 type: ACTUAL name: Silodosin measure: Urine growth factors level measure: Urine growth factors level measure: Urine growth factors level sex: MALE minimumAge: 50 Years maximumAge: 80 Years stdAges: ADULT stdAges: OLDER_ADULT facility: En Chu Kong Hospital city: New Taipei City zip: 23702 country: Taiwan lat: 25.01111 lon: 121.44583 hasResults: False
nctId: NCT06282705 id: 306347 briefTitle: Dose Response Effect of Drop Jumps on Bone Characteristics overallStatus: COMPLETED date: 2023-01-06 date: 2023-12-13 date: 2023-12-13 date: 2024-02-28 date: 2024-02-28 name: Nottingham Trent University class: OTHER briefSummary: The study aims to assess if a 16-week drop jump intervention from different heights shows different bone adaptations. Participants will complete four visits over a period of 16 weeks. An initial consultation will be conducted to ensure participants meet the inclusion criteria following participant recruitment. Estimated load being applied to the bone, will be assessed using non-invasive biomechanical procedures (Inertial Measurement Units, motion analysis, force plates) during drop jumps. Participants will be assigned a drop jump height of 0 cm, 30 cm or 60 cm based on a significant difference in external load at these heights or assigned to a control group where no jumps will be performed. Groups will be matched for body mass to ensure that jump height produces the load. The participants will be asked to perform 40 jumps (20 each side), 4 times per week ensuring jumping bouts are separated by 24 hours. Bone characteristics will be assessed via whole body dual-energy X-ray absorptiometry (DXA) scans and bilateral peripheral Quantitative Computed Tomography (pQCT) scans. Lab based jumping will take place on week 0, week 6, week 12, and week 16 to understand the loading applied during the different jump height groups. pQCT scans will take place on week 0, week 12, week 16 and DXA scans will take place week 0 and week 16. The reasoning of week 12 for pQCT being it may show a significant timepoint for bone formation during the remodelling cycle. During visits participants will complete a health screen, the Bone specific Physical Activity Questionnaire (BPAQ), a food frequency questionnaire and Pittsburgh sleep quality questionnaire alongside consent as tools to monitor any changes to participant lifestyle across the study. Differences in bone characteristics, lab measures and jump heights will be analysed between and within participants.
The present study aims to use varied drop jump heights to identify an osteogenic dose response effect. Drop jumps have been previously used to expose osteogenic effects in research due to the load produced at impact. Is it possible to identify an optimum height for bone response during impact? If so do we then find anything above this height actually has negative or no effect on a group of individuals? conditions: Healthy Participants conditions: Low Activity Level studyType: INTERVENTIONAL phases: NA allocation: RANDOMIZED interventionModel: PARALLEL interventionModelDescription: Semi-randomised, matched model. primaryPurpose: BASIC_SCIENCE masking: NONE count: 48 type: ACTUAL name: Diagonal Drop Jumps 0cm name: Diagonal Drop Jumps 40cm name: Diagonal Drop Jumps 60cm measure: BMD as assessed by whole body dual-energy X-ray absorptiometry (DXA). measure: BMC as assessed by whole body dual-energy X-ray absorptiometry (DXA). measure: Total bone area as assessed by whole body dual-energy X-ray absorptiometry (DXA). measure: Trabecular density as assessed by peripheral quantitative tomography (pQCT) of tibia. measure: Cortical thickness as assessed by peripheral quantitative tomography (pQCT) of tibia. measure: Periosteal circumference as assessed by peripheral quantitative tomography (pQCT) of tibia. measure: Axial bone strength (SSIX) as assessed by peripheral quantitative tomography (pQCT) of tibia. measure: Axial bone strength (SSIY) as assessed by peripheral quantitative tomography (pQCT) of tibia. measure: Polar bone strength (SSIPOL) as assessed by peripheral quantitative tomography (pQCT) of tibia. measure: Cortical density as assessed by peripheral quantitative tomography (pQCT) of tibia. measure: Peak impact load as assessed by force plates. measure: Impulse as assessed by force plates. measure: Load rate as assessed by force plates. measure: Jump height as assessed by force plates. measure: Centre of Mass (CoM) velocity as assessed by force plates. measure: Peak acceleration as assessed by Inertial measurement units (IMU). measure: Stiffness as assessed by motion capture. measure: Moments as assessed by motion capture. sex: ALL minimumAge: 18 Years maximumAge: 25 Years stdAges: ADULT facility: Nottingham Trent University city: Nottingham state: Nottinghamshire zip: Ng11 8NS country: United Kingdom lat: 52.9536 lon: -1.15047 hasResults: False
nctId: NCT06282692 id: UNAIR-MP-INAKTIF-R-005 briefTitle: INAVAC Vaccine Phase III (Immunobridging Study) in Healthy Population Aged 12 to 17 Years Old overallStatus: RECRUITING date: 2023-06-19 date: 2024-05-19 date: 2024-07-19 date: 2024-02-28 date: 2024-02-28 name: Dr. Soetomo General Hospital class: OTHER_GOV name: Indonesia-MoH name: Universitas Airlangga name: PT Biotis Pharmaceuticals, Indonesia briefSummary: This is an open label, phase III trial - immunobridging study. There will be only 1 group in the study. All subjects (12 to 17 years old) will receive INAVAC 5 µg dose. The vaccine will be administered with 2-dose schedule, intramuscularly, with 28 day interval. All subjects will be followed for 12 months.
INAVAC is an inactivated vaccine made of SARS-CoV-2 virus isolated from a patient in Surabaya, composed with aluminium hydroxy gel, tween 80, and L-histidine, and this study will be the first phase III in adolescents. conditions: COVID-19 Pandemic conditions: COVID-19 Vaccines studyType: INTERVENTIONAL phases: PHASE3 allocation: NA interventionModel: SINGLE_GROUP primaryPurpose: PREVENTION masking: NONE maskingDescription: This is an open label, phase III trial - immunobridging study. There will be only 1 group in the study. All subjects (12 to 17 years old) will receive INAVAC 5 µg dose.